MedTrace Logo

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Conditions

  • Solid Advanced Tumor
  • Lymphoma
  • NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG

Part A: OSE-279 100mg

Human IgG4 mAb against PD-1

DRUG

Part A: OSE-279 300mg

Human IgG4 mAb against PD-1

DRUG

Part A: OSE-279 600mg

Human IgG4 mAb against PD-1

DRUG

Part B: OSE-279 600 mg and OSE2101

OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

DRUG

Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

DRUG

Part C: OSE-279 600 mg - HLA-A2 positif

OSE-279: Human IgG4 mAb against PD-1

DRUG

Part C: OSE-279 600 mg - HLA-A2 negative

OSE-279: Human IgG4 mAb against PD-1

Sponsors & Collaborators

  • OSE Immunotherapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751798 on ClinicalTrials.gov